Pilot study of atomoxetine in patients with Parkinson’s disease and dopa-unresponsive Freezing of Gait
© Revuelta et al. 2015
Received: 5 October 2015
Accepted: 8 December 2015
Published: 10 December 2015
Freezing of gait (FoG) is a common and debilitating condition in Parkinson’s disease (PD) associated with executive dysfunction. A subtype of FoG does not respond to dopaminergic therapy and may be related to noradrenergic deficiency. This pilot study explores the effects of atomoxetine on gait in PD patients with dopa-unresponsive FoG using a novel paradigm for objective gait assessment.
Ten patients with PD and dopa-unresponsive FoG were enrolled in this eight-week open label pilot study. Assessments included an exploratory gait analysis protocol that quantified spatiotemporal parameters during straight-away walking and turning, while performing a dual task. Clinical, and subjective assessments of gait, quality of life, and safety were also administered. The primary outcome was a validated subjective assessment for FoG (FOG-Q). Atomoxetine was well tolerated, however, no significant change was observed in the primary outcome. The gait analysis protocol correlated well with clinical scales, but not with subjective assessments. DBS patients were more likely to increase gait velocity (p = 0.033), and improved in other clinical assessments.
Objective gait analysis protocols assessing gait while dual tasking are feasible and useful for this patient population, and may be superior correlates of FoG severity than subjective measures. These findings can inform future trials in this population.
Freezing of gait (FoG) is a common and disabling symptom for patients with Parkinson’s disease (PD). FoG may respond to dopaminergic therapies and DBS early in the course, of PD, and later become dopa-unresponsive [1, 2]. Noradrenergic deficiency has been well documented in PD and has long been proposed as a potential etiology for FoG , in addition attention deficit and executive dysfunction have also been strongly associated with FoG [4, 5]. However, multiple trials of noradrenergic medications have yielded conflicting results . There is currently no accepted objective measure of FoG severity.
Atomoxetine (ATM) is a norepinephrine reuptake inhibitor shown to improve attention deficit in adults  and executive dysfunction in PD , with reports of improvements in FoG . In this study we explore the effects of ATM on multiple gait parameters in patients with PD who experience dopa-unresponsive FoG using multiple assessments as potential outcome measures of FoG. The purpose of this study is to gather pilot data to be used to aid in the design of larger randomized clinical trials of therapeutic agents for the treatment of dopa-unresponsive FoG.
Subjects (ages 18–80) with PD (Hoehn and Yahr stage 2–4) and dopa-unresponsive-FoG were recruited for this study. All patients met UK-Brain Bank criteria for idiopathic PD, had a positive response to item 14 of the Unified Parkinson’s Disease Rating Scale (UPDRS), and were observed to have actual FoG at screening, in the on state. Subjects must be on stable medications for 3 months prior to starting the study, and had to be able to walk 20 feet without an assistive device. Subjects who were intolerant or hypersensitive to the drug class, were on monoamine oxidase inhibitors, were demented (MMSE < 26), whose gait dysfunction was attributable to other conditions, had narrow angle glaucoma, pheochromocytoma, severe cardiovascular conditions, uncontrolled hypertension, symptomatic tachyarrhythmias, uncontrolled depression or suicidal ideation, were excluded from the study. All subjects underwent medical clearance prior to enrolling in the study. The Institutional Review Board of the Medical University of South Carolina approved the study and investigational new drug (IND) exception was granted by the Food and Drug Administration.
This was an open-label, forced titration, 8-week study to explore the safety, tolerability and efficacy of atomoxetine for the treatment of dopa-unresponsive FoG in patients with PD. A 3-point change in the Freezing of Gait Questionnaire (FOG-Q) was chosen as the primary efficacy outcome measure in order to power this pilot study. A sample size of 10 patients treated with atomoxetine would have 80 % power to detect a pre-post reduction in the mean FOG-Q score of 2.6, assuming a standard deviation of the difference of 3.0, using a paired t-test with a 0.05 one-sided significance level. The estimate of the standard deviation of the change was based on literature . Exploratory efficacy outcome measures were: changes in spatiotemporal parameters while performing a dual cognitive task, reduction in falls, clinical global improvement (CGI) and changes in clinical gait outcome measures (see gait assessments). Fisher’s exact test was used to test the null hypothesis that the proportion of responders was the same for patients who received DBS or did not.
All patients underwent a screening visit prior to enrollment. Patients who enrolled in the study were started on 40 mg daily for two weeks then increased to 40 mg twice daily for the 4-week treatment period. They were then reduced to 40 mg daily for one week, and washed out for two weeks. Full gait evaluations occurred at baseline (Visit 2), after the 4-week treatment period at full dose (Visit 4), and after washout (Visit 5). Visit 3 was a safety only visit without gait assessments.
Safety and tolerability
Safety was assessed by reported adverse events, UPDRS parts 1–4 scores, Falls Efficacy (FES) questionnaire, EKG, vital sign assessments, and liver function tests.
Gait assessments were performed in the “relative on state” defined as 1–2 h after taking their medication, with their DBS on (when applicable), and patient report of feeling in the on state. The FOG-Q was administered with each gait assessment at baseline (Visit 2), after the 4-week treatment period at full dose (Visit 4), and after washout (Visit 5).
The Dynamic Gait Index (DGI) and the Tinetti Gait and Balance assessments were administered. Falls incidence and FES were also administered.
Ten patients who met all inclusion and exclusion criteria were enrolled in the study. There were no early withdrawals or terminations from the study. The mean age was 67.1 years, there were eight males, and three patients were status post bilateral subthalamic nucleus DBS.
Safety and tolerability
All ten patients tolerated the study drug well; there were no drug discontinuation, drug dose adjustments, or withdrawals. Seven of ten patients had eight adverse events, all of which were mild. Three patients had mild increases in creatine which subsided on repeat testing. Miscellaneous reports of increase in creatine (3), worsening FoG (1), diarrhea (1), worsening dyskinesia (1), nausea (1), were recorded but resolved spontaneously, are were not deemed clinically significant or related to study drug. Another subject reported feeling mildly “jittery” and improved after washout. This was not deemed clinically significant but was likely related to study drug. There were no observed increases in blood pressure, EKG changes, palpitations, arrhythmias, or changes in liver function. There was no change in UPDRS scores to suggest worsening of motor symptoms.
Changes in clinical scales pre and post treatment
Changes in spatiotemporal parameters pre and post treatment
FOG-Q scores did not correlate with values for objective spatiotemporal parameters with or without concurrent dual task performance, including time to turn. However, time to turn was highly correlated with clinical measures of gait severity including: Dynamic Gait Index (p = 0.006) and Tinetti (p = 0.012); as well as with PD severity scales including: UPDRS motor (p = 0.02) and total score (p = 0.056). In most instances dual tasking improved the association further: Dynamic Gait Index (p = 0.001), UPDRS motor (p = 0.013) and total score (p = 0.028).
We controlled for performance on cognitive abilities by rating their ability to perform the cognitive tasks while walking. There was no consistent improvement or worsening in their performance in these tasks ensuring there was no significant practice effect and there was a consistent difficulty level across visits.
A post-hoc analysis was performed where a subgroup who had a greater than 0.09 m/s improvement in velocity from baseline to the post treatment visit in their self-selected walking speed was further evaluated. This cutoff was based on published minimal detectable change for self-selected walking speed for PD patients . Four patients were found to have increased walking speed based on these criteria. All three DBS “responded” and in fact, DBS patients were more likely to have improvement beyond 12 cm/s in velocity (p = 0.033). Further analysis of this subgroup revealed a decrease in FOG-Q scores greater than 3 points (pre-specified clinically significant change) as well as significant decreases in CGI score (2 points) and PDQ-39 scores (12.61 points). This group of patients also had a reduction in time to turn with and without a concurrent cognitive task.
We report the results of an eight-week open label study designed to explore the effects of atomoxetine on gait parameters in patients with PD and dopa-unresponsive FoG. Since dopa-unresponsive FoG is by definition not a dopaminergic phenomenon, a noradrenergic agent was chosen, and gait assessments were designed to capture attention deficit and executive dysfunction by utilizing increased cognitive load paradigms. The study did not meet its primary endpoint of an improvement of three points on the FOG-Q, however, important observations were made. Atomoxetine was safe and well tolerated in this patient population. DBS patients were more likely to have clinically significant increases in walking speed, FoG (as assessed by FOG-Q), time to turn while dual tasking, and quality of life (as assessed by PDQ-39). This may be explained by the fact that DBS patients who have good control of other PD motor symptoms (dopa-responsive symptoms) and still freeze provide a particularly good model for the target population of this study (dopa-unresponsive freezers).
Regarding the spatiotemporal data we report the feasibility of this protocol for the quantification of gait parameters, including time to turn, on two electronic walkways. Furthermore, we found time to turn to be a strong correlate of gait disturbance severity in this cohort, particularly under the dual task condition, and found no correlation between any of the measured objective parameters and the FOGQ. This may be related to the subjective nature of this measure.
This study was supported by the Barmore Fund for Parkinson’s Research, the MUSC Department of Neurology and Neurosurgery, by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, supported by NIH/NCATS Grant Number UL1TR000062, and by NIH NINDS Grant Number 1K23NS091391-01A1.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Schaafsma JD, Balash Y, Gurevich T, Bartels AL, Hausdorff JM, Giladi N. Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson’s disease. Eur J Neurol. 2003;10(4):391–8.View ArticlePubMedGoogle Scholar
- Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol. 2011;10(8):734–44.View ArticlePubMedGoogle Scholar
- Grimbergen YA, Langston JW, Roos RA, Bloem BR. Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother. 2009;9(2):279–90. doi:10.1586/14737184.108.40.2069.View ArticlePubMedGoogle Scholar
- Yogev G, Giladi N, Peretz C, Springer S, Simon ES, Hausdorff JM. Dual tasking, gait rhythmicity, and Parkinson’s disease: which aspects of gait are attention demanding? Eur J Neurosci. 2005;22(5):1248–56.View ArticlePubMedGoogle Scholar
- Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord. 2008;23(3):329–42. doi:10.1002/mds.21720. quiz 472.View ArticlePubMedGoogle Scholar
- Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose–response study. Pediatrics. 2001;108(5):E83.View ArticlePubMedGoogle Scholar
- Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study. Mov Disord. 2009;24(2):277–82. doi:10.1002/mds.22307.PubMed CentralView ArticlePubMedGoogle Scholar
- Jankovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284(1–2):177–8.View ArticlePubMedGoogle Scholar
- Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, et al. Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord. 2009;24(5):655–61. doi:10.1002/mds.21745.View ArticlePubMedGoogle Scholar
- Bloem BR, Valkenburg VV, Slabbekoorn M, Willemsen MD. The Multiple Tasks Test: development and normal strategies. Gait Posture. 2001;14(3):191–202.View ArticlePubMedGoogle Scholar
- Combs SA, Diehl MD, Filip J, Long E. Short-distance walking speed tests in people with Parkinson disease: reliability, responsiveness, and validity. Gait Posture. 2014;39(2):784–8. doi:10.1016/j.gaitpost.2013.10.019.View ArticlePubMedGoogle Scholar